Serum lipids in primary sclerosing cholangitis
| Autor: | Keith D. Lindor, Emmanouil Sinakos, Roberta A. Jorgensen, Ghulam Abbas |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Lipoproteins Cholangitis Sclerosing Blood lipids Hyperlipidemias Coronary Artery Disease Placebo Gastroenterology Primary sclerosing cholangitis chemistry.chemical_compound Cholestasis Risk Factors Internal medicine Hyperlipidemia medicine Humans Triglycerides Retrospective Studies Hepatology Cholesterol business.industry Ursodeoxycholic Acid Middle Aged medicine.disease Lipids Ursodeoxycholic acid Stroke chemistry Female lipids (amino acids peptides and proteins) business Dyslipidemia Follow-Up Studies medicine.drug |
| Zdroj: | Digestive and Liver Disease. 44:44-48 |
| ISSN: | 1590-8658 |
| DOI: | 10.1016/j.dld.2011.07.020 |
| Popis: | Background Limited data are available regarding the serum lipids in primary sclerosing cholangitis. Aims To determine the lipid levels in patients with primary sclerosing cholangitis. Methods We monitored the serum lipid levels annually for up to 6 years in 157 patients included in three previous trials of ursodeoxycholic acid. Results The baseline lipid values were: total cholesterol = 207 mg/dL (127–433); high-density lipoprotein = 56 mg/dL (26–132); low-density lipoprotein = 129 mg/dL (48–334); triglycerides = 102 mg/dL (41–698). Cirrhotic stage was associated with lower levels of total cholesterol (186 mg/dL vs. 217 mg/dL, p = .02). A significant correlation between the liver biochemistries and total and low-density lipoprotein cholesterol levels was observed. Ursodeoxycholic acid, as compared to placebo, significantly decreased total (−27 mg/dL vs. 22 mg/dL, p = .0004) and low-density lipoprotein cholesterol (−24 mg/dL vs. 17 mg/dL, p = .0001). After extended follow-up, small changes in the lipid levels were noticed. The incidence of coronary artery disease was 4%. Conclusions Our findings suggest that the lipid levels in primary sclerosing cholangitis are often above levels where treatment with lipid-lowering agents is recommended. However, primary sclerosing cholangitis patients seem to have no elevated risk for cardiovascular events. The correlation of total and low-density lipoprotein cholesterol with liver biochemistries implies that mechanisms linked to cholestasis may regulate cholesterol metabolism. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect